Skip to main content

NY State Grants Clinical Lab Permit to Agendia

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Amsterdam-based Agendia said today that New York regulators have granted the firm a clinical laboratory permit, enabling it to receive commercial samples for its MammaPrint breast cancer recurrence assay from NY state residents.

The company said that with the latest permit from the New York State Department of Health, it has all major US clinical laboratory licenses. The firm's MammaPrint test, which is a multivariate index assay, received marketing clearance from the US Food and Drug Administration three years ago.

Agendia also said that the College of American Pathologists has accredited the firm's lab in Huntington Beach, Calif.

"The growing clinical importance of complex genomic testing means that our laboratories need to meet the highest standards of quality for patients and health care professionals," Agendia CEO Bernhard Sixt said in a statement, adding that the permit from New York is "recognized as the most difficult to obtain."

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.